Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates

Core Insights - Bausch Health (BHC) reported quarterly earnings of $1.21 per share, exceeding the Zacks Consensus Estimate of $1.12 per share, and showing an increase from $1.15 per share a year ago, representing an earnings surprise of 8.04% [1] - The company generated revenues of $2.56 billion for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.89% and increasing from $2.41 billion year-over-year [2] - Bausch shares have underperformed the market, losing approximately 21.1% since the beginning of the year, while the S&P 500 has gained 4.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.89 on revenues of $2.26 billion, and for the current fiscal year, it is $4.31 on revenues of $9.89 billion [7] - The estimate revisions trend for Bausch is mixed, leading to a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which Bausch belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]